NEW YORK, December 21, 2017 /PRNewswire/ --
According to New Frontier Data, the legal cannabis market was worth an estimated $6.6 billion in
2016, and is projected to grow at a compound annual growth rate (CAGR) of 16% to reach over $24
billion by 2025. The medical market is projected to show strong growth at 12% CAGR through 2025, growing from $4.7 billion in 2016 to an estimated $13.3 billion in 2025. During the same
period, sales of cannabis products for recreational use (adult-use) are projected to grow at a 21% CAGR, from $1.9 billion to $10.9 billion. The projections are based on data from states
where cannabis has been legalized as of January 2017, and do not include any potential legalization
initiatives throughout the forecast period. Pivot Pharmaceuticals Inc. (OTC: PVOTF), Emblem Corp. (OTC: EMMBF), Namaste
Technologies Inc. (OTC: NXTTF), Cannabis Wheaton Income Corp. (OTC: CBWTF), Emerald Health Therapeutics Inc. (OTC: EMHTF)
Major markets for the cannabis industry, such as the state of California, are expected to
become examples of how to manage the new and growing cannabis industry. Giadha Aguirre de Carcer, New Frontier Data CEO,
explained, "Significant changes are already underway in California for medical cannabis and
adult use laws, which we see will have major implications for the cannabis industry, including ecommerce and delivery services in
the state… As the largest state in the country - and the largest potential market for cannabis products - the implications for
the growth of the industry because of California's adult use market cannot be overstated."
Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) also just listed this week on the Canadian Stock Exchange under the Ticker
'PVOT'. Yesterday the company announced breaking news that, "the Company has signed a Binding Letter of Intent to acquire ERS
Holdings, LLC ("ERS"), a privately-held California company. ERS has developed a patented
technology called "RTIC" - Ready To Infuse Cannabis ("the Patent"), and has also filed several continuation patents relating to
the transformation of cannabis oil into powder for infusion into a variety of food and beverage products such as capsules,
K-Cups, stick packs, baked mixes, liquid shots, protein shakes, topicals, lotions, and bottled beverages.
In exchange for 100% of ERS Holdings, LLC (Patent Portfolio and Trademarks for "Instant THC™" and "Instant CBD™") Pivot will
pay ERS Holdings USD $1,000,000 and 5,000,000 Common Shares ("The Shares") of Pivot Pharmaceuticals
Inc. The Shares will be subject to a six (6) month restriction with the first 25% of the total number of Shares to be released
six (6) months following the closing date, with 25% to be released every quarter thereafter, as per the escrow agreement to be
executed at the same time as the Definitive Agreement. Completion of the acquisition is subject to regulatory approval and
standard closing conditions.
Current cannabis product formulations are either poorly absorbed topicals and orals or inhaled and smoked carcinogens. Health
conscious adults who seek the therapeutic benefits of cannabis without the negative health effects represent a large untapped
demographic. This demographic is also inundated with edible product choices that are high in sugar, such as candy or
confectionary. Health seeking consumers who use cannabis daily represent a large market opportunity for Pivot. The acquisition of
ERS allows Pivot to add to its growing pipeline of cannabis based products.
Invented by Ross Franklin and Ed Rosenthal, the invention
"relates generally to methods and compositions of matter for enabling concentrated cannabis oil to be stable, emulsifiable and
flavorless for use in hot beverages or food by combining cannabis oil with a starch powder or starch-derived powder. Embodiments
also relate to a variety of culinary uses for the stabilized, emulsified, flavorless concentrated cannabis oil powder."
Mr. Franklin, ERS' CEO, said that "after being courted by some of Canada's largest cannabis
companies, we selected the Pivot team to help monetize our patent. Their management team has extensive pharmaceutical and
nutraceutical industry experience and an impressive track record of bringing products to market. In addition to the food and
beverage markets, we also look forward to integrating "RTIC" into Pivot's current topical, oral and nanoparticulate
pipeline."
Dr. Patrick Frankham, CEO of Pivot Pharmaceuticals stated that "Pivot believes that the
anticipated changes in cannabis regulation in Canada and California will provide an opportunity to launch multiple products into the healthcare and recreational
markets in 2018. We are delighted that Ross Franklin and Pat Rolfes
from ERS have chosen Pivot to help transform their patents and processes into therapeutic consumer goods. Pivot is in ongoing
discussions with several Canadian Licensed Producers and Licensed Dealers in order to accelerate commercialization of our large
pipeline of technology driven products. If a suitable joint venture partner is not identified by January
2018 Pivot will seek a Licensed Dealer designation from Health Canada and commence construction of its own production
facility. As a result, Pivot has engaged CBRE, the world's largest commercial real estate firm, to help facilitate the site
selection process."
Emblem Corp. (OTC: EMMBF) is a fully integrated licensed producer and distributor of medical cannabis and cannabis
derivatives in Canada under the ACMPR (Access to Cannabis for Medical Purposes Regulations). On
December 18th, the company announced the launch of four cannabis oils that can now be ordered
online or by phone from its award-winning customer service team. "We are particularly excited by our CBD oils," says Nick Dean, CEO of Emblem Corp. "CBD is not psychoactive, and a recent report from the World Health
Organization suggests CBD to be an effective treatment for epileptic seizures, amongst a number of other medical conditions.
Physicians are increasingly turning to CBD-rich strains for their patients."
Namaste Technologies Inc. (OTCQB: NXTTF) is an emerging leader in vaporizer and accessories space. Recently, the company
announced a Letter of Intent with Supreme Pharmaceuticals Inc. The LOI, signed by Supreme's wholly owned subsidiary, 7ACRES, and
Namaste's wholly owned subsidiary, Cannmart Inc. ("CannMart"), provides that Supreme will supply CannMart with a premium range of
high quality dried cannabis flower which will be offered in the Company's medical marketplace. Supreme is focused on producing
high quality cannabis through a commitment to carefully curated genetics, quality focused cultivation practices and a
post-harvest process that includes a 14-day whole plant drying process and hand finishing of each flower. Under the terms of the
LOI, Namaste has committed to work with Supreme as a preferred vendor as related to possible branded partnerships, in addition to
supply for Namaste's in-house branded medical cannabis. All Supreme cannabis will bear the 7ACRES producer's mark. Namaste
believes that Supreme's Business to Business (B2B) distribution model fits well with Namaste's focus on becoming Canada's leading online retailer for medical cannabis.
Cannabis Wheaton Income Corp. (OTCQB: CBWTF) is the first cannabis streaming company in the world. On November 1, 2017, the company announced the closing of the acquisition of all of the issued and outstanding
shares of RockGarden Medicinals (2014) Inc. pursuant to the terms of a definitive share purchase agreement dated October 31, 2017. The Acquisition furthers the Company's streaming platform strategy by providing the Company
additional resources and regulatory tools to help accelerate Wheaton Licensing Program participants' pathway to licensing under
the Access to Cannabis for Medical Purposes Regulations (the "ACMPR"). Located in Carleton Place,
Ontario, RockGarden is a privately owned licensed producer of cannabis pursuant to the ACMPR. On August 25, 2017 RockGarden was granted a cultivation license.
Emerald Health Therapeutics Inc. (OTCQX: EMHTF) subsidiary Emerald Health Botanicals Inc. is a licensed Producer under
Canada's Access to Cannabis for Medical Purposes Regulations ("ACMPR") and is authorized to
produce and sell dried medical cannabis flower and medical cannabis oil. On November 29th, the
company announced that its licensed producer application, submitted through Emerald Health Botanicals for its new Richmond, BC greenhouse facility under Canada's ACMPR has met the
requirements of the paper-based review of Health Canada's Office of Medical Cannabis ("OMC"). The OMC confirmed satisfactory
provision of information regarding the security plan, record keeping and tracking systems, QA reports, and security clearance for
key personnel, among other items. Emerald aims to harvest from this new 75,000 square feet of cultivation space by 3Q 2018 and
plans to have over 500,000 square feet of cultivation space built at this site by year end. "With significant, secure supply from
our large-scale Pure Sunfarms partnership and Emerald facilities, and our value-added product development plans, we intend to be
well-positioned for growth in the adult use market in the near and long term," said Dr. Avtar
Dhillon, Executive Chairman of Emerald.
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News,
Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company
Interviews. A pioneer in the financially driven digital space, video production and integration of social media,
FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination,
branding, marketing and advertising for third parties for corporate news and original content through our unique media platform
that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial
Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not
undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided
[exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into
media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials
for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the
information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting
high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com
does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along
with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our
unique financial newswire and media platform. For this release, FinancialBuzz.com expects to be compensated five thousand dollars for financial news dissemination and PR services by pivot pharmaceuticals inc. Our fees
may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a
combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance
is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or
cash payments for financial news dissemination and PR advertising. FinancialBuzz.com does not undertake to update any of the
information on the editorial or Site or continue to post information about any companies the information contained herein is not
intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation.
The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members
and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site,
company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors
accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation
of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and
website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time.
None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any
particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication
is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment
strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree
to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no
representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change
without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not
guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com.
Media Contact:
info@financialbuzz.com
+1-877-601-1879
Url: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com